Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 12/2016

01-11-2016 | Thoracic Oncology

PSF1 (Partner of SLD Five 1) is a Prognostic Biomarker in Patients with Non-small Cell Lung Cancer Treated with Surgery Following Preoperative Chemotherapy or Chemoradiotherapy

Authors: Ryu Kanzaki, MD, Hisamichi Naito, MD, PhD, Kazuyoshi Kise, MD, PhD, Kazuhiro Takara, PhD, Daisuke Eino, MD, Masato Minami, MD, PhD, Yasushi Shintani, MD, PhD, Soichiro Funaki, MD, PhD, Tomohiro Kawamura, MD, PhD, Toru Kimura, MD, PhD, Meinoshin Okumura, MD, PhD, Nobuyuki Takakura, MD, PhD

Published in: Annals of Surgical Oncology | Issue 12/2016

Login to get access

Abstract

Background

PSF1 (Partner of SLD Five 1) is an evolutionarily conserved DNA replication factor that is part of the GINS (Go, Ichi, Nii, and San) complex . The objective of this study was to evaluate the relationship between PSF1 expression and prognosis in patients with non-small cell lung cancer (NSCLC) treated with surgery following preoperative chemotherapy or chemoradiotherapy.

Methods

Sixty-nine patients with NSCLC treated with surgery following preoperative chemotherapy or chemoradiotherapy who did not achieve pathologic complete response were enrolled. The status of PSF1 expression was evaluated by immunohistochemistry, and the relationship between expression of PSF1 and Ki-67 was determined, as well as correlations between PSF1 expression and prognosis.

Results

We found that 27 of 69 patients’ tumors (39 %) were positive for PSF1 expression. The Ki-67 index was significantly higher in the PSF1-positive versus the PSF1-negative group (p = 0.0026). Five-year, disease-free survival of the PSF1-positive group was significantly worse (17.7 vs. 44.3 %, p = 0.0088), and the 5-year overall survival also was worse (16.6 vs. 47.2 %, p = 0.0059). Moreover, PSF1 expression was found to be a significant independent prognostic factor for shorter survival by Cox multivariate analysis (hazard ratio 2.43, 95 % confidence interval 1.27–4.60, p = 0.0076).

Conclusions

PSF1 is a useful prognostic biomarker to stratify NSCLC patients treated with surgery following preoperative chemotherapy or chemoradiotherapy.
Literature
1.
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. Cancer J Clin. 2014;64:9–29.CrossRef
2.
NCSLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375:1267–77.CrossRef
3.
Hamada C, Tanaka F, Ohta M, Fujimura S, Kodama K, imaizumi M, Wada H. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol. 2005;23:4999–5006.CrossRefPubMed
4.
Japan Lung Cancer Society. The clinical guide line for lung cancer, 3rd ed. Tokyo: Kanehara; 2014.
5.
Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86:673–80.CrossRefPubMed
6.
Rosell R, Gomezcodina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung-cancer. N Engl J Med. 1994;330:153–8.CrossRefPubMed
7.
Toyooka S, Kiura K, Takemoto M, et al. Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg. 2012;14:565–9.CrossRefPubMedPubMedCentral
8.
Yokomise H, Gotoh M, Okamoto T, et al. Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007;133:1179–85.CrossRefPubMed
9.
Inoue M, Okumura M, Minami M, et al. Cardiopulmonary co-morbidity: a critical negative prognostic predictor for pulmonary resection following preoperative chemotherapy and/or radiation therapy in lung cancer patients. Gen Thorac Cardiovasc Surg. 2007;55:315–321.CrossRefPubMed
10.
Shintani Y, Funakoshi Y, Inoue M, Takeuchi Y, Okumura M, Ohta M. Pathological status of mediastinal lymph nodes after preoperative concurrent chemoradiotherapy determines prognosis in patients with non-small cell lung cancer. Ann Thorac Cardiovasc Surg. 2012;18:530–5.CrossRefPubMed
11.
Takayama Y, Kamimura Y, Okawa M, Muramatsu S, Sugino A, Araki H. GINS, a novel multiprotein complex required for chromosomal DNA replication in budding yeast. Genes Dev. 2003;17:1153–65.CrossRefPubMedPubMedCentral
12.
Bauerschmidt C, Pollok S, Kremmer E, Nasheuer HP, Grosse F. Interactions of human Cdc45 with the Mcm2-7 complex, the GINS complex, and DNA polymerases delta and epsilon during S phase. Genes Cells. 2007;12:745–58.PubMed
13.
Gambus A, Jones RC, Sanchez-Diaz A, Kanemaki K, van Deursen F, Edmondson RD, Labib K. GINS maintains association of Cdc45 with MCM in replisome progression complexes at eukaryotic DNA replication forks. Nat Cell Biol. 2006;8:358–66.CrossRefPubMed
14.
Kanemaki M, Sanchez-Diaz A, Gambus A, Labib K. Functional proteomic identification of DNA replication proteins by induced proteolysis in vivo. Nature. 2003;423:720–4.CrossRefPubMed
15.
Moyer SE, Lewis PW, Botchan MR. Isolation of the Cdc45/Mcm2-7/GINS (CMG) complex, a candidate for the eukaryotic DNA replication fork helicase. Proc Natl Acad Sci. 2006;103:10236–41.CrossRefPubMedPubMedCentral
16.
Pacek M, Tutter AV, Kubota Y, Takisawa H, Walter JC. Localization of MCM2-7, Cdc45, and GINS to the site of DNA unwinding during eukaryotic DNA replication. Mol Cell. 2006;21:581–7.CrossRefPubMed
17.
18.
Ueno M, Itoh M, Sugihara K, Asano M, Takakura N. Both alleles of PSF1 are required for maintenance of pool size of immature hematopoietic cells and acute bone marrow regeneration. Blood. 2009;113:555–62.CrossRefPubMed
19.
Nagahama Y, Ueno M, Miyamoto S, et al. PSF1, a DNA replication factor expressed widely in stem and progenitor cells, drives tumorigenic and metastatic properties. Cancer Res. 2010;70:1215–24.CrossRefPubMed
20.
Kinugasa Y, Matsui T, Takakura N. CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment. Stem Cells. 2014;32:145–56.CrossRefPubMed
21.
Matsui T, Kinugasa Y, Tahara H, Kanakura Y, Takakura N. Possible role of mural cell-covered mature blood vessels in inducing drug resistance in cancer-initiating cells. Am J Pathol. 2013;182:1790–9.CrossRefPubMed
22.
Nakahara I, Miyamoto M, Shibata T, et al. Up-regulation of PSF1 promotes the growth of breast cancer cells. Genes Cells. 2010;15:1015–24.CrossRefPubMed
23.
Tahara H, Naito H, Kise K, et al. Evaluation of PSF1 as a prognostic biomarker for prostate cancer. Prostate Cancer Prostatic Dis. 2015;18:56–62.CrossRefPubMed
24.
Zhou L, Sun XJ, Liu C, et al. Overexpression of PSF1 is correlated with poor prognosis in hepatocellular carcinoma patients. Int J Biol Markers. 2015;30:e56–64.CrossRefPubMed
25.
Japanese Lung Cancer Society. The general rule for clinical and pathological record of lung cancer. 7th ed. Tokyo: Kanehara; 2010.
26.
Thomas M, Rube C, Hoffknecht P, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol. 2008;9:636–48.CrossRefPubMed
27.
Shien K, Toyooka S, Ichimura K, et al. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer. 2012;77:162–7.CrossRefPubMed
28.
Tamura M, Sawabata N, Kobayashi S, et al. Prognostic significance of p21 protein expression in patients with pulmonary squamous cell carcinoma following induction chemotherapy. Ann Thorac Cardiovasc Surg. 2007;13:9–14.PubMed
29.
Jakobsen JN, Sorensen JB. Clinical impact of ki-67 labeling index in non-small cell lung cancer. Lung Cancer. 2013;79:1–7.CrossRefPubMed
30.
Planchard D, Loriot Y, Goubar A, Commo F, Soria JC. Differential expression of biomarkers in men and women. Semin Oncol. 2009;36:553–65.CrossRefPubMed
Metadata
Title
PSF1 (Partner of SLD Five 1) is a Prognostic Biomarker in Patients with Non-small Cell Lung Cancer Treated with Surgery Following Preoperative Chemotherapy or Chemoradiotherapy
Authors
Ryu Kanzaki, MD
Hisamichi Naito, MD, PhD
Kazuyoshi Kise, MD, PhD
Kazuhiro Takara, PhD
Daisuke Eino, MD
Masato Minami, MD, PhD
Yasushi Shintani, MD, PhD
Soichiro Funaki, MD, PhD
Tomohiro Kawamura, MD, PhD
Toru Kimura, MD, PhD
Meinoshin Okumura, MD, PhD
Nobuyuki Takakura, MD, PhD
Publication date
01-11-2016
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 12/2016
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5392-z

Other articles of this Issue 12/2016

Annals of Surgical Oncology 12/2016 Go to the issue

Breast Oncology

Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response

Reconstructive Oncology

Fasciocutaneous Lotus Petal Flap for Perineal Wound Reconstruction after Extralevator Abdominoperineal Excision: Application for Reconstruction of the Pelvic Floor and Creation of a Neovagina

Pediatric Oncology

Improvements in the Treatment of Patients Suffering from Bladder-Prostate Rhabdomyosarcoma: A Report from the CWS-2002P Trial

Colorectal Cancer

Effect of Neoadjuvant Radiation Dose and Schedule on Nodal Count and Its Prognostic Impact in Stage II–III Rectal Cancer

Hepatobiliary Tumors

Posttreatment Surveillance in Patients with Prolonged Disease-Free Survival After Resection of Colorectal Liver Metastasis

Colorectal Cancer

Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer